Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2025-04-24 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯关于向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普莱柯生物工程股份有限公司 regarding the application for a comprehensive credit facility from a bank. It details the credit amount, types of credit, authorization by the board, and the validity period of the credit facility. There is no financial report, earnings data, or detailed financial statements included. The document is about financing activities and capital structure optimization, specifically the application for credit lines. This fits the definition of a Capital/Financing Update (CAP). The document length is short but contains substantive information about financing, not just a notice or report publication announcement.
2025-04-24 Chinese
普莱柯2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度 关于公司募集资金存放与使用情况的专项报告" which translates to a "2024 Annual Special Report on the Deposit and Use of Raised Funds". It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange related to the management and use of raised funds. The content details the amount of funds raised, their usage, management, cash management activities, and compliance with regulatory requirements. It includes detailed tables on fund usage and investment projects, and mentions approvals by the board and disclosures on the stock exchange website. This type of document is a specialized report focused on the company's capital raising activities and the use of those funds, which fits the category of Capital/Financing Update (CAP). It is not a full annual report, earnings release, or other types of filings. The document length is substantial and contains detailed financial and operational data related to capital usage, not just an announcement or certification. Therefore, the best classification is CAP with high confidence.
2025-04-24 Chinese
普莱柯对会计师事务所2024年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (立信会计师事务所) for the 2024 audit engagement of 普莱柯生物工程股份有限公司. It discusses the audit firm's qualifications, independence, and the audit procedures performed for the 2024 financial statements and internal control audit. The document includes details about the audit committee's review and the board's approval to reappoint the auditor. It is not the audit report itself but an assessment of the auditor's performance and compliance with auditing standards. The document length is short (1444 characters), and it does not contain actual financial statements or detailed audit results but rather an evaluation of the auditor's work. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information about audit procedures and results, excluding full annual reports.
2025-04-24 Chinese
普莱柯董事会审计委员会对会计师事务所2024年度履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the performance and supervision of the external audit firm (立信会计师事务所) for the fiscal year 2024. It details the audit firm's qualifications, the process of reappointment, the scope and results of the audit, and the committee's evaluation of the audit firm's work. The document includes references to the audit report issued by the firm, but it is not the audit report itself. It is a supervisory report by the audit committee on the audit firm's performance and independence during the annual audit process. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and related supervisory information, excluding full annual reports. The document length is 2314 characters, which is relatively short but contains substantive content about audit supervision rather than just an announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2025-04-24 Chinese
独立董事2024年度述职报告(王楚端)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2024 of 普莱柯生物工程股份有限公司. It details the independent director's duties, attendance at board and committee meetings, opinions on related party transactions, communication with auditors and shareholders, and overall evaluation of the director's performance. It does not contain financial statements or quarterly/annual financial results, nor is it an announcement of voting results or management changes. It is a report on the independent director's activities and compliance with governance rules, which fits best under Board/Management Information (MANG) as it relates to board members' roles and responsibilities rather than a financial report or regulatory filing. The document length is 4016 characters, which is relatively short but contains substantive content about board member duties rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2025-04-24 Chinese
立信会计师事务所（特殊普通合伙）关于普莱柯生物工程股份有限公司2024年度募集资金存放与使用情况的鉴证报告
Regulatory Filings
2025-04-24 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.